Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Predictive Oncology Inc (POAI)
:POAI
Holding POAI?
Track your performance easily
Earnings Data
Report Date
Apr 08, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.86Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2018
|% Change Since: 53.16%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in AI-driven biomarker discovery, strategic partnerships, and cost reduction initiatives, despite a decline in quarterly revenue and consolidation of non-profitable operations.Company Guidance
During the Predictive Oncology Second Quarter 2024 Earnings Call, the company provided guidance on several strategic initiatives and financial metrics. Key highlights included the completion of a multiyear ovarian cancer study, which utilized data from 235 patients and resulted in the training of 160 predictive models with high accuracy. The company also launched a novel 3D cell culture technology and reported progress in its ACE initiative, forming a collaboration with the University of Michigan. Financially, Predictive Oncology reported a net loss of $3.2 million for the quarter, with a revenue of $279,000, compared to $490,000 in the previous year. They highlighted a strategic cost reduction initiative expected to save approximately $2.5 million annually, and capital raises totaling $5.0 million to bolster their cash position.Successful Retrospective Ovarian Cancer Study
Completion of a multiyear ovarian cancer study with UPMC Magee-Womens Hospital, expanding AI capabilities to discover novel biomarkers for oncology.
Launch of 3D Cell Culture Technology
Introduction of a novel 3D cell culture technology that mimics human tissue architecture more closely, enhancing drug candidate testing and reducing development costs.
ACE Initiative and Collaboration
First collaboration with the University of Michigan under the ACE program, providing access to a large library of natural product drug candidates.
Cost Reduction Initiative
Strategic cost reduction measures, including consolidation of operations from Birmingham to Pittsburgh, expected to reduce annual cash usage by $2.5 million.
Capital Raises
Raised $5.0 million through capital raises to bolster cash balance and extend runway.
---
POAI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
POAI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.79 | $0.81 | +2.53% |
| Aug 14, 2024 | $0.99 | $0.87 | -12.12% |
| May 15, 2024 | $1.74 | $1.74 | 0.00% |
| Mar 28, 2024 | $2.55 | $2.27 | -10.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Predictive Oncology Inc (POAI) report earnings?
Predictive Oncology Inc (POAI) is schdueled to report earning on Apr 08, 2025, TBA Not Confirmed.
What is Predictive Oncology Inc (POAI) earnings time?
Predictive Oncology Inc (POAI) earnings time is at Apr 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is POAI EPS forecast?
POAI EPS forecast for the fiscal quarter 2024 (Q4) is -0.25.
---